CD86 and meningioma: Our analysis of leukocyte activation markers revealed no difference in the relative expression of canonical T lymphocyte activation markers, IL2RA/CD25, CD40LG/CD154, and CD69, but higher expression of activated antigen presenting cell marker CD86 in NF2 meningiomas when compared with TRAF7 tumors.